NY-ESTÉE-LAUDER
12.4.2021 13:02:25 CEST | Business Wire | Press release
Today, The Estée Lauder Companies (NYSE:EL) (ELC) announced that after 13 years with the company, Alexandra (Alex) Trower, Executive Vice President, Global Communications, will retire effective July 1, 2021. The successor to Alex’s role will be announced at a later date.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210412005450/en/
“Alex has been a highly respected thought-leader, collaborative partner, and a trusted senior business advisor,” said Fabrizio Freda, President and CEO, The Estée Lauder Companies. “Leveraging her deep expertise across financial, corporate, consumer and crisis communications, Alex has continuously evolved our strategic communications priorities to drive and support the rapid growth of our business. She built a truly outstanding, global, multi-disciplinary organization and has led her team with wisdom and grace, continuously strengthening the delicate balance of art and science that is ever-present in the world of communications.”
William P. Lauder, Executive Chairman, The Estée Lauder Companies, added: “Against the backdrop of an increasingly complex global landscape, Alex has delivered thoughtful, effective communications to our valued stakeholders, strategically elevating our winning business narrative, rich culture, compelling heritage and distinctive ELC brand equity. She is an outstanding communicator and skilled strategist, and her incredible character, steadfast integrity and deep empathy will be greatly missed across the organization.”
Since joining The Estée Lauder Companies in 2008, Alex has been the architect of ELC’s Global Communications function as it stands today: a highly operationalized, flexible, worldwide and regional structure that prioritizes local relevance, functional expertise and brand-building acumen. Under her leadership, Global Communications has strategically expanded across regions; and through close partnership with regional and affiliate leaders, the department plays a critical role in supporting the company's continued strong regional growth.
Among her many accomplishments, Alex has strategically elevated the company’s reputation worldwide. In 2016, she oversaw the launch of the company’s refreshed Corporate Brand, which represented a transformational change in where, how and why the company engages with its stakeholders. Through this lens, Alex and her team have enabled the organization to communicate boldly, quickly and in more intentional and transparent ways, with an emphasis on strengthening and modernizing the platforms that most resonate with its audiences.
Alex has been a champion of ELC’s efforts across philanthropy, Citizenship and Sustainability, and Inclusion, Diversity and Equity. She serves as a Board member of The Estée Lauder Companies’ Charitable Foundation, is a founding member of the company’s Diversity Council, and served as the first Executive Co-Sponsor of wELCome, the company’s LGBTQA employee resource group.
Mentoring, leading and cultivating talented women is Alex’s passion, which was borne out of her experience as a student at Hollins University, one of the country’s leading women’s universities, where she now serves as the Chair of the Board of Trustees. In 2018, Alex was recognized by New York Women in Communications with a prestigious Matrix Award, presented to her by William P. Lauder in recognition of her exceptional leadership and contributions across the industry. She served as the Co-Chair of the Board of Directors for the International Women’s Media Foundation (IWMF), which supports female journalists worldwide. In 2014, she received the IWMF’s Corporate Leadership Award in recognition of her more than 15 years of service and fundraising.
“I am incredibly proud of all that my team and I have accomplished,” said Alex Trower. “ELC’s Global Communications organization has consistently advanced ahead of the curve, seamlessly partnering with stakeholders across the company and the industry to drive and support the continued success of our business. While the decision to retire is of course bittersweet, I know that the talented Global Communications team is well positioned for its next chapter of growth. On a personal note, it has been an absolute pleasure to serve in this role alongside the Lauder Family and the exceptional ELC executive leadership team.”
About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc.
is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, Tommy Hilfiger, M·A·C, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin, TOM FORD BEAUTY, Smashbox, Ermenegildo Zegna, AERIN, RODIN olio lusso, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, BECCA, Too Faced and Dr. Jart+.
ELC-L
ELC-C
View source version on businesswire.com: https://www.businesswire.com/news/home/20210412005450/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom